It aimed to evaluate the injection’s safety, immunogenicity and pharmacokinetics against Orencia, with all subjects receiving ...

Orencia has been on the market for rheumatoid arthritis since 2995, with an additional FDA approval for a subcutaneous formulation in 2011 and new indications in psoriatic arthritis and juvenile ...